BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 6849356)

  • 21. [Studies on the viability of trophoblast after termination of various kinds of pregnancies (author's transl)].
    Kanda K
    Nihon Sanka Fujinka Gakkai Zasshi; 1980 Oct; 32(10):1575-82. PubMed ID: 6263995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study).
    Curry SL; Schlaerth JB; Kohorn EI; Boyce JB; Gore H; Twiggs LB; Blessing JA
    Am J Obstet Gynecol; 1989 Apr; 160(4):805-9; discussion 809-11. PubMed ID: 2540654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of human chorionic gonadotropin (hCG) in combination with a 500 calorie diet on clinical and laboratory parameters in premenopausal women with and without hormonal contraception].
    Rabe T; Richter S; Kiesel L; Zaloumis M; Runnebaum B
    Aktuel Endokrinol Stoffwechsel; 1987 Jul; 8(3):142-9. PubMed ID: 12281505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay.
    Wilcox AJ; Weinberg CR; Armstrong EG; Canfield RE
    Fertil Steril; 1987 Feb; 47(2):265-9. PubMed ID: 3817172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norplant implants: the mechanism of contraceptive action.
    Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
    Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
    Gynecol Oncol; 2017 Nov; 147(2):364-370. PubMed ID: 28927899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma beta-subunit human chorionic gonadotropin assay in molar pregnancy and choriocarcinoma.
    Yuen BH; Cannon W; Benedet JL; Boyes DA
    Am J Obstet Gynecol; 1977 Apr; 127(7):711-2. PubMed ID: 557901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post coital contraception.
    Haspels AA; Van Santen MR
    J Gynaecol Endocrinol; 1986; 2(1-2):17-24. PubMed ID: 12269214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of drugs and intrauterine devices for birth control.
    Meeker CI
    N Engl J Med; 1969 May; 280(19):1058-60. PubMed ID: 4180710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
    Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
    Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contraception--retrospect and prospect.
    Harper MJ
    Prog Drug Res; 1977; 21():293-407. PubMed ID: 339271
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O
    BMJ; 1993 Apr; 306(6883):956-63. PubMed ID: 8490470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.